Cord Blood Transplant for Children and Young Adults with Blood Cancers and Non-Cancerous Disorders

Sponsor: Memorial Sloan Kettering Cancer Center

Sponsor score: 60

ClinicalTrials ID:NCT04644016

This study is exploring the use of cord blood transplants in children and young adults with serious blood cancers and other life-threatening blood disorders who do not have a suitable donor for a traditional transplant.

Patient Parameters

Program Overview

This clinical trial is focused on using cord blood transplants to treat children and young adults with severe blood cancers and non-cancerous blood disorders. The study aims to understand the safety and effectiveness of this treatment in patients who do not have a matched donor for a traditional bone marrow transplant. Cord blood, which is collected from the umbilical cord after birth, is used because it can be a good alternative when a suitable donor is not available.

Eligibility Criteria

Inclusion Criteria

  • Children and young adults aged 21 or younger without a suitable donor for a traditional transplant.
  • Diagnosed with certain types of blood cancers like acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL) at high risk of returning or not responding to treatment.
  • Diagnosed with other blood disorders like myelodysplastic syndrome (MDS) or myeloproliferative disorders (MPD) that are life-threatening.
  • Diagnosed with high-risk non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL) that is not in remission.
  • Diagnosed with certain inherited metabolic disorders early in the disease, such as Hurler Syndrome or Metachromatic Leukodystrophy.
  • Diagnosed with non-cancerous blood disorders like hemoglobinopathies or bone marrow failure syndromes.
  • Must have good organ function and be in relatively good health, with specific blood and organ function levels.
  • Must meet specific criteria for cord blood transplant, including matching and cell count requirements.

Exclusion Criteria

  • Poor overall health or organ function.
  • Advanced metabolic disease.
  • Active leukemia in the central nervous system.
  • Progression of indolent NHL or Hodgkin lymphoma after recent treatment.
  • Diagnosed with myelofibrosis or other cancers with significant bone marrow issues.
  • Recent autologous stem cell transplant within the last 6 months.
  • Previous allogeneic stem cell transplant.
  • Active and uncontrolled infections at the time of transplant.
  • HIV infection or positive for HTLV-1.
  • Pregnant or breastfeeding.
  • Unable to provide informed consent or follow the treatment plan.

Locations

FACILITYZIPCITYSTATE
Memorial Sloan Kettering Cancer Center10065New YorkNew York

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.